论文部分内容阅读
作者在1985年对~(131)I治疗Graves病后远期并发甲减随访的基础上,采用HS-TSH(IRMA)、FT_s、TSH、TT_3、TT_4、FT_4I、TRH兴奋试验及MCA、TGA、胆固醇、甘油三脂等项目测定,并结合临床症状、体征对26例(治疗年限平均9.5a)患者进行随访,通过对上述指标比较,指出TSH诊断符合率最高,胆固醇、FT_4I其次,甲减的并发似与患者甲状腺抗体(MCA、TGA)存在有关,并认为~(131)Ⅰ治疗后患者长期随访TSH、FT_4I及胆固醇,有助于及早发现并发甲减和对甲减在替代治疗中病情控制的判断。
On the basis of long-term follow-up of hypothyroidism after ~ (131) I treatment of Graves disease in 1985, the authors used HS-TSH (IRMA), FT_s, TSH, TT_3, TT_4, FT_4I, TRH excitatory test and MCA, TGA, Cholesterol, triglyceride and other items, and combined with clinical symptoms and signs of 26 patients (average 9.5 years of treatment) were followed up by comparing the above indicators, the highest coincidence rate of TSH diagnosis, cholesterol, FT_4I followed by hypothyroidism Concurrent resection is associated with the presence of thyroid antibodies (MCA, TGA). It is believed that long-term follow-up of TSH, FT_4I, and cholesterol in patients with ~ (131) Ⅰ may facilitate early detection of concurrent hypothyroidism and concomitant hypothyroidism during replacement therapy Judgment.